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OBJECTIVES: To determine a proﬁle of renal transplant recip-
ients (RTRs) who are at highest risk for immunosuppressant
therapy (IST) non-adherence. METHODS: Retrospective analy-
sis was performed on follow-up non-adherence data routinely
reported by transplant centers to the United Network for Organs
Sharing in the United States Renal Data System. Those who
received transplants on or after January 1, 1995, had at least 36
months of follow-up data, and did not receive a second renal
transplant were included in the analyses. Random effects logit
regression was used to estimate risk of non-adherence while con-
trolling for age, race, education, donor type, primary insurance
and IST including cyclosporine (CSA), tacrolimus (TAC), aza-
thioprine (AZA), mycophenolate mofetil (MMF) and steroids.
Association between IST non-adherence and graft failure was
also examined. RESULTS: 53,997 individuals met the inclusion
criteria. Mean age at time of transplant was 44 years (SD = 15).
Sixty percent were male, 74% were Caucasian, 29% had college
education, and 39% had living donor transplants. At time of
transplant, 5% were on Medicaid and 44% were on Medicare.
CSA, TAC, AZA, MMF and steroids were used by 61%, 34%,
13%, 72% and 97% of RTRs, respectively. About 5.5% of RTRs
were reported as non-adherent and 3% had graft failure within
36 months post-transplant. Non-adherence risk increased with
time and decreased with age (p < 0.001). RTRs who were male,
non-Caucasian, not on Medicare, or used MMF or TAC had
higher risk for non-adherence, with odds ratios (OR) of 1.4, 2.0,
1.6, 1.1, and 1.3 respectively (p < 0.05), while RTRs who used
CSA, steroids or AZA had lower risk (OR = 0.8, 0.5 and 0.7
respectively, p < 0.001). Non-adherent RTRs had higher risk for
graft failure (OR = 5.2, p < 0.001). CONCLUSION: Interven-
tions aimed at improving adherence should target younger RTRs,
male RTRs, non-Caucasian RTRs, and those not on Medicare to
reduce risk of graft failure.
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OBJECTIVES: Haemoglobin cycling is common in haemodialy-
sis patients receiving erythropoiesis-stimulating agents (ESAs). It
is uncertain whether different ESAs are associated with greater
ﬂuctuations in haemoglobin. The purpose of this study was to
compare the within-patient variability in haemoglobin levels in
haemodialysis patients receiving intravenous epoetin alfa or
intravenous darbepoetin alfa. METHODS: Data on haemodial-
ysis patients were extracted from the Renal Anaemia Manage-
ment (RAM) database from 2003 to 2004. The variance in
haemoglobin was calculated for each patient with more than one
haemoglobin observation (n = 4751). A mixed-effects analysis of
variance model was ﬁtted to the within-patient variances and
weighting was based on the number of observations minus 1 for
each patient. The model allowed the treatment comparisons to
be undertaken after taking into account the situations where
patients have data on both products and can hence act as their
own control. RESULTS: The mean within-patient variance in
haemoglobin levels for patients receiving darbepoetin alfa was
23% (95% CI: 16% to 29%) greater than that for patients
receiving epoetin alfa (p < 0.0001). The mean haemoglobin level
for patients receiving darbepoetin alfa was 11.33 g/dL (95% CI:
11.27, 11.38) compared with 11.41 g/dL (95% CI: 11.38, 11.45)
for patients receiving epoetin alfa (p = 0.008). CONCLUSION:
There was greater within-patient ﬂuctuation in haemoglobin
levels in patients receiving darbepoetin alfa compared with
epoetin alfa. The implications of haemoglobin ﬂuctuations on
patient outcomes and resource use require further study.
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OBJECTIVES: To compare the within-patient variability in
haemoglobin levels in pre-dialysis or peritoneal dialysis patients
receiving intravenous epoetin alfa or intravenous darbepoetin
alfa. METHODS: Data on pre-dialysis (n = 169) and peritoneal
dialysis (n = 162) patients were extracted from the Renal
Anaemia Management (RAM) database from 2003 to 2004. The
variance in haemoglobin was calculated for each patient with
more than one haemoglobin observation. A mixed-model was
ﬁtted to the within-patient variances and weighting was based
on the number of observations minus 1 for each patient. The
model took into account the situation where patients had data
on both agents and could therefore act as their own control.
RESULTS: The mean within-patient variance in haemoglobin
levels for pre-dialysis patients receiving darbepoetin alfa was
63% (95% CI: 1% to 163%) greater than that for patients
receiving epoetin alfa (p = 0.045). The mean haemoglobin level
for patients receiving darbepoetin alfa was 10.34 g/dL (95% CI:
9.94, 10.80) compared with 11.22 g/dL (95% CI: 10.95, 11.50)
for patients receiving epoetin alfa (p = 0.001). For peritoneal
dialysis patients, those administered darbepoetin alfa had similar
within-patient variability in haemoglobin levels compared to
those receiving epoetin alfa (darbepoetin 10% greater than
epoetin alfa, 95% CI: −28% to 66%, p = 0.7). The mean haemo-
globin level for patients receiving darbepoetin alfa was 11.49
g/dL (95% CI: 11.19, 11.78) compared with 11.16 g/dL (95%
CI: 10.81, 11.50) for patients receiving epoetin alfa (p = 0.14).
CONCLUSION: In spite of the small sample size, there was a
signiﬁcantly greater within-patient ﬂuctuation in haemoglobin
levels in pre-dialysis patients receiving darbepoetin alfa com-
pared with epoetin alfa, while no difference was seen in peri-
toneal dialysis patients. The implications of haemoglobin
ﬂuctuations on patient outcomes and resource use require further
study.
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OBJECTIVES: The objective of this study is to estimate the ﬁve-
year impact on costs associated with hospitalization in patients
under renal replacement therapy (RRT) when a shift in treatment
modality from hemodialysis (HD) to peritoneal dialysis (PD) is
assumed. METHODS: An Excel-based budget impact model
(BIM) was developed to assess the impact of a shift in treatment
modality share. Model inputs included dialysis modality shares,
